Stockscreener 앱 받기
11.13
3.30%
-0.38
시간 외 거래:
11.31
0.18
+1.62%
전일 마감가:
$11.51
열려 있는:
$11.6
하루 거래량:
1.37M
Relative Volume:
0.88
시가총액:
$1.24B
수익:
$577.74M
순이익/손실:
$-149.78M
주가수익비율:
-7.95
EPS:
-1.4
순현금흐름:
$-78.21M
1주 성능:
-1.68%
1개월 성능:
-36.44%
6개월 성능:
-49.98%
1년 성능:
-42.30%
1일 변동 폭
$11.11
$11.69
1주일 범위
$11.11
$11.94
52주 변동 폭
$10.91
$34.13
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
NVCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
11.13 | 1.27B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
134.28 | 227.88B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.14 | 152.55B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
377.58 | 143.34B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.88 | 114.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.35 | 46.11B | 5.69B | 4.14B | 577.90M | 6.96 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-12-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-10-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
Statistical indicators supporting NovoCure Limited’s strengthFree High Accuracy Alerts for ROI Traders - Newser
NovoCure's Optune Study for Glioblastoma Treatment: A Potential Game-Changer in the Market - AInvest
Is NovoCure Limited trending in predictive chart modelsAsset Growth Pattern and Return Summary - Newser
Short interest data insights for NovoCure LimitedTechnical Confirmation System with Signal Alerts - Newser
Detecting price anomalies in NovoCure Limited with AILow Drawdown Stock Screener with Analysis - Newser
NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer? - TipRanks
Real time scanner hits for NovoCure Limited explainedAI Short-Term Gain Forecast with Data - Newser
How institutional ownership impacts NovoCure Limited stockFree Triple Digit Return Stock Predictions - Newser
How strong is NovoCure Limited company’s balance sheetRapid wealth multiplication - Jammu Links News
What are analysts’ price targets for NovoCure Limited in the next 12 monthsCapitalize on emerging market sectors - Jammu Links News
How volatile is NovoCure Limited stock compared to the marketBreakthrough profit margins - Jammu Links News
Is NovoCure Limited stock poised for growthAnnual Market Behavior and Sector Summary - Newser
Chief Financial Officer of NovoCure Christoph Brackmann Buys 339% More Shares - simplywall.st
NovoCure (NVCR) Sales Rise but Losses Deepen—Is Profitability or Growth the Bigger Priority? - simplywall.st
NovoCure (NASDAQ:NVCR) Shares Up 9.3% After Insider Buying Activity - Defense World
Novocure’s Earnings Call: Clinical Successes & Cautious Optimism - TipRanks
NovoCure CFO Makes a Bold Move: Christoph Brackmann Purchases $231,800 Worth of Stock - AInvest
NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead - Seeking Alpha
Will NovoCure Limited stock benefit from AI tech trendsWeekly Entry Signal Based Forecast Tool - Newser
Multi asset correlation models including NovoCure LimitedFree Low Risk Buy Zone Opportunity Watch - Newser
Why NovoCure Stock Is Cratering Today - Mitrade
NovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Call Transcript - Insider Monkey
Does NovoCure Limited show high probability of reboundSafe Entry Strategy with High Win Rate - Newser
What are NovoCure Limited company’s key revenue driversDiscover undervalued stocks before they soar - Jammu Links News
Top 3 Health Care Stocks That May Explode In July - inkl
Wells Fargo & Company Reaffirms Equal Weight Rating for NovoCure (NASDAQ:NVCR) - Defense World
NovoCure Q2 2025 Earnings Highlights: Revenue Growth Amidst Challenges - AInvest
NovoCure Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
NovoCure: Q2 Earnings Snapshot - Norwalk Hour
NovoCure Limited 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NVCR) - Seeking Alpha
Bank of New York Mellon Corp Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $38 - 富途牛牛
NovoCure Limited Stock Analysis and ForecastBreakneck growth rates - Autocar Professional
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Gr - GuruFocus
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
Novocure Ltd. Reports Q2 2025 Financial Results - TipRanks
Novocure Beat Revenue Expectations As Patient Numbers Grew - Finimize
How NovoCure Limited stock performs during market volatilityTargeted 200 Percent Gain - Newser
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
자본화:
|
볼륨(24시간):